India synthesises nanoparticles to treat cancer

Institute of Advanced Study in Science and Technology (IASST) have synthesised new magnetic nanoparticles that can be used to treat cancer. This is reported by IANS, a partner of TV BRICS.

The nanocrystalline particles in question are cobalt chromite nanocrystalline particles doped with gadolinium. This compound is capable of heating cancer cells to a temperature of about 46 degrees Celsius, which causes necrosis of tumour tissues.

The heating occurs under the influence of an external magnetic field – this method is called magnetic hyperthermia. It is considered less toxic than classical chemotherapy and radiotherapy, and more affordable than targeted therapy or stem cell transplantation.

However, the researchers note that temperature control in magnetotherapy remains a challenge: the physical properties of the particles make it difficult to heat evenly and safely. The new development brings the method closer to practical application in oncology.

Cancer is a common name for a group of diseases in which the body’s cells begin to divide uncontrollably and form malignant tumours. These cells can invade surrounding tissues and spread throughout the body – a process called metastasis. Cancer treatment depends on the type and stage of the disease and may include chemotherapy, radiation therapy, surgery, and new techniques such as immunotherapy or nanomedicine. – tvbrics.com

Related Posts

Pensioner ordered to pay US$120 maintenance for four children

  Sharon Jiyamwa Herald reporter The Harare Civil Court has ordered a local man to pay US$120 or its Zimbabwe-dollar equivalent per month towards the upkeep of his four minor…

Transboundary tourism blueprint to unlock US$5 billion economy unveiled at Sanganai/Hlanganani Expo

  Thupeyo Muleya Beitbridge Bureau The Government has outlined an ambitious plan to transform Zimbabwe’s South-East Lowveld in the Greater Limpopo Transfrontier Conservation Area (GLTFCA) into a high-value transboundary safari…

Leave a Reply

Your email address will not be published. Required fields are marked *